Peng CY - Search Results

1

Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks.

Fung SK, Pan CQ, Wong GL, Seto WK, Ahn SH, Chen CY, Hann HL, Jablkowski MS, Kim YJ, Yurdaydin C, Peng CY, Nguyen T, Yatsuhashi H, Flaherty JF, Yee LJ, Abramov F, Wang H, Abdurakhmanov D, Lim YS, Buti M. Fung SK, et al. Among authors: peng cy. Aliment Pharmacol Ther. 2024 Jan;59(2):217-229. doi: 10.1111/apt.17764. Epub 2023 Oct 31. Aliment Pharmacol Ther. 2024. PMID: 37905449

2

Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-naïve Taiwanese patients with chronic hepatitis B.

Chien RN, Peng CY, Kao JH, Hu TH, Lin CC, Hu CT, Chen CY, Hsieh TY, Lin HC, Chuang WL; Taiwan NA-Registry Group. Chien RN, et al. Among authors: peng cy. J Gastroenterol Hepatol. 2014 Jan;29(1):185-92. doi: 10.1111/jgh.12416. J Gastroenterol Hepatol. 2014. PMID: 24354995

3

Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II).

Zeuzem S, Flisiak R, Vierling JM, Mazur W, Mazzella G, Thongsawat S, Abdurakhmanov D, Van Kính N, Calistru P, Heo J, Stanciu C, Gould M, Makara M, Hsu SJ, Buggisch P, Samuel D, Mutimer D, Nault B, Merz M, Bao W, Griffel LH, Brass C, Naoumov NV; ESSENTIAL II Study Group. Zeuzem S, et al. Aliment Pharmacol Ther. 2015 Oct;42(7):829-44. doi: 10.1111/apt.13342. Epub 2015 Aug 4. Aliment Pharmacol Ther. 2015. PMID: 26238707 Clinical Trial.

4

All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study.

Kao JH, Lee YJ, Heo J, Ahn SH, Lim YS, Peng CY, Chang TT, Torbeyns A, Hughes E, Bhore R, Noviello S. Kao JH, et al. Among authors: peng cy. Liver Int. 2016 Oct;36(10):1433-41. doi: 10.1111/liv.13128. Epub 2016 Apr 28. Liver Int. 2016. PMID: 27009831 Clinical Trial.

5

Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1.

Kao JH, Yu ML, Peng CY, Heo J, Chu CJ, Chang TT, Lee YJ, Hu TH, Yoon KT, Paik SW, Lim YS, Ahn SH, Isakov V, McPhee F, Hu W, Scott Swenson E, Yin PD, Treitel M. Kao JH, et al. Among authors: peng cy. J Gastroenterol Hepatol. 2017 Dec;32(12):1998-2005. doi: 10.1111/jgh.13796. J Gastroenterol Hepatol. 2017. PMID: 28370350

6

Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study.

Kao JH, Yu ML, Chen CY, Peng CY, Chen MY, Tang H, Chen Q, Wu JJ. Kao JH, et al. Among authors: peng cy. J Gastroenterol Hepatol. 2018 Aug;33(8):1507-1510. doi: 10.1111/jgh.14096. Epub 2018 Mar 12. J Gastroenterol Hepatol. 2018. PMID: 29346834 Clinical Trial.

7

Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection.

Seto WK, Asahina Y, Brown TT, Peng CY, Stanciu C, Abdurakhmanov D, Tabak F, Nguyen TT, Chuang WL, Inokuma T, Ikeda F, Santantonio TA, Habersetzer F, Ramji A, Lau AH, Suri V, Flaherty JF, Wang H, Gaggar A, Subramanian GM, Mukewar S, Brunetto MR, Fung S, Chan HL. Seto WK, et al. Among authors: peng cy. Clin Gastroenterol Hepatol. 2018 Jun 20:S1542-3565(18)30633-5. doi: 10.1016/j.cgh.2018.06.023. Online ahead of print. Clin Gastroenterol Hepatol. 2018. PMID: 29933096

8

Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan.

Liu CH, Yu ML, Peng CY, Hsieh TY, Huang YH, Su WW, Cheng PN, Lin CL, Lo CC, Chen CY, Chen JJ, Ma Q, Brooks-Rooney C, Kao JH. Liu CH, et al. Among authors: peng cy. Aliment Pharmacol Ther. 2018 Dec;48(11-12):1290-1300. doi: 10.1111/apt.15011. Epub 2018 Oct 25. Aliment Pharmacol Ther. 2018. PMID: 30362139

9

Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study.

Liu CH, Yu ML, Peng CY, Hsieh TY, Huang YH, Su WW, Cheng PN, Lin CL, Lo CC, Chen CY, Chen JJ, Ma Q, Brooks-Rooney C, Kao JH. Liu CH, et al. Among authors: peng cy. J Formos Med Assoc. 2019 Jun;118(6):1014-1023. doi: 10.1016/j.jfma.2018.10.020. Epub 2018 Nov 15. J Formos Med Assoc. 2019. PMID: 30448077 Free article.

10

Editorial: identifying candidates for pegylated interferon add-on to entecavir therapy in patients with HBeAg-positive chronic hepatitis B.

Peng CY. Peng CY. Aliment Pharmacol Ther. 2019 Mar;49(5):609-610. doi: 10.1111/apt.15136. Aliment Pharmacol Ther. 2019. PMID: 30746775 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

627 results

Search Page

Filters